Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

FDA Approval of Daraxonrasib in Pancreatic Cancer

11 September 2026 · By · Wire by Fusion42

Published

11 September 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at onclive.com →

◆ Verified

Fusion42 · 12 September 2026 · Fusion42 review

The FDA approved daraxonrasib, the first pan-RAS targeted therapy for metastatic pancreatic cancer, demonstrating improved overall survival, progression-free survival, and quality of life compared to chemotherapy. This approval marks a paradigm shift in treatment strategies and opens new clinical trial pathways.

This Wire brief sits within Fusion42's coverage of Biotech, and 50 sources have reported it between 26 Aug 2026 and 11 Sep 2026.

◆ ◆ The Wire takeaway

Your pancreatic cancer treatment biotech just gained a new competitor redefining survival benchmarks. Daraxonrasib's approval expands who you must outperform and sets a new standard for clinical trial design.

◆ Coverage

50 sources · first reported 26 Aug 2026 · latest 11 Sep 2026

◆ Related on Wire

◆ Topics

Biotechfda-approvalpancreatic-cancertargeted-therapyclinical-trialsbiotech-drug